10 assets in X-Linked Lymphoproliferative Syndrome

Therapeutic assets addressing X-Linked Lymphoproliferative Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Thiotepa X-Linked Lymphoproliferative Syndrome	University of Florida	P2	BB (64)
Cyclophosphamide X-Linked Lymphoproliferative Syndrome	Masonic Cancer Center, University of Minnesota	P2	B (57)
Alemtuzumab X-Linked Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Fludarabine X-Linked Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Melphalan X-Linked Lymphoproliferative Syndrome	Washington University School of Medicine	P2	CCC (53)
Icaspase9-Transduced T Cells X-Linked Lymphoproliferative Syndrome	Baylor College of Medicine	P1	CC (43)
Rimiducid X-Linked Lymphoproliferative Syndrome	Baylor College of Medicine	P1	CC (43)
Busulfanum X-Linked Lymphoproliferative Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna X-Linked Lymphoproliferative Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Nivestim X-Linked Lymphoproliferative Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)